US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Emera Inc.

51.38

-0.1900-0.37%

Post-market: 51.380.00000.00%17:20 EDT

Volume:370.56K

Turnover:18.98M

Market Cap:15.50B

PE:20.84

High:51.57

Open:51.57

Low:51.00

Close:51.57

52wk High:53.91

52wk Low:43.90

Shares:301.75M

Float Shares:298.86M

Volume Ratio:0.68

T/O Rate:0.12%

Dividend:2.09

Dividend Rate:4.07%

EPS(TTM):2.47

EPS(LYR):2.47

ROE:8.17%

ROA:2.96%

PB:1.80

PE(LYR):20.84

Loading ...

Overview Company News Filings

Emera reports Q4 adjusted EPS 55c, consensus 42c

Emera extends adjusted EPS growth target of 5%-7% through 2030

Earnings Flash (EMA) Emera Posts Q4 Adjusted EPS CA$0.55, vs. FactSet Est of CA$0.57

MT Newswires Live

AstraZeneca marketing authorization application for Enhertu validated by EMA

NervGen Pharma to Participate at Upcoming Investor Conferences

OS Therapies Discloses 2026 Timeline For Lead Drug Regulatory Filings

Cellectar Biosciences Expands Global Intellectual Property Estate

Shiba Inu (SHIB) Momentum Slows as Price Tests 200-EMA Resistance

Earning Preview: Emera Inc. Q4 revenue is expected to decrease by 52.39%, and institutional views are neutral-to-cautious

NervGen Pharma Announces Retirement of Chief Financial Officer, Bill Adams

Press Release: ORYZON Announces Appointment of Rolando Gutierrez-Esteinou, M.D., as Chief Medical Officer for CNS

Press Release: Celyad Oncology Announces the Sale of C-CATHez (R) Catheter

Press Release: Ipsen delivers strong results in 2025, driven by solid execution across all therapeutic areas, and provides 2026 guidance

Protalix Highlights Positive EMA Opinion on Elfabrio Dosing

Desjardins Sticks to Their Hold Rating for Emera (EMA)

NervGen Pharma to Present at Unite2Fight Paralysis’ 20th Annual Science and Advocacy Symposium

Enlivex Treasury Portfolio Update: New Listing of the RAIN Token on Kraken, the Second-Largest U.S. Cryptocurrency Exchange

NervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company’s Growth and Execution of Its Mission in Spinal Cord Injury

Neuren's Regulatory Hurdles for Trofinetide May Push Back EU Royalties, Says Jefferies

MT Newswires Live

Neuren Pharmaceuticals (ASX:NEU) Is Down 16.1% After EMA Setback on Trofinetide Approval Prospects

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/EMA/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"EMA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EMA\",,,,,undefined,":{"symbol":"EMA","market":"US","secType":"STK","nameCN":"Emera Inc.","latestPrice":51.38,"timestamp":1774641600000,"preClose":51.57,"halted":0,"volume":370557,"hourTrading":{"tag":"盘后","latestPrice":51.38,"preClose":51.38,"latestTime":"17:20 EDT","volume":63754,"amount":3282296.947854,"timestamp":1774646419620,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.003684312584836101,"floatShares":298863171,"shares":301745499,"eps":2.465138,"marketStatus":"Market Closed","change":-0.19,"latestTime":"03-27 16:00:00 EDT","open":51.57,"high":51.57,"low":50.995,"amount":18977370.102801,"amplitude":0.01115,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":2.465138,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1774857600000},"marketStatusCode":7,"adr":0,"exchange":"NYSE","adjPreClose":51.57,"dividendRate":0.041461,"postHourTrading":{"tag":"盘后","latestPrice":51.38,"preClose":51.38,"latestTime":"17:20 EDT","volume":63754,"amount":3282296.947854,"timestamp":1774646419620,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.6803560531561107,"impliedVol":0.1992,"impliedVolPercentile":0.6099},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EMA\",,,,,undefined,":{"symbol":"EMA","floatShares":298863171,"roa":"2.96%","roe":"8.17%","lyrEps":2.465138,"volumeRatio":0.6803560531561107,"shares":301745499,"dividePrice":2.092586,"high":51.57,"amplitude":0.01115,"preClose":51.57,"low":50.995,"week52Low":43.9012,"pbRate":"1.80","psRate":"2.45","week52High":53.91,"institutionHeld":0,"latestPrice":51.38,"eps":2.465138,"divideRate":0.040728,"volume":370557,"delay":0,"ttmEps":2.465138,"open":51.57,"prevYearClose":49.24,"prevWeekClose":51.27,"prevMonthClose":52.04,"prevQuarterClose":49.24,"fiveDayClose":51.27,"twentyDayClose":52.04,"sixtyDayClose":49.32,"dividendPayoutRate":0.8394110571990734,"dividendFrequency":"Q","dividendGrowthYears":0,"fiveYearAvgDividendRate":0.04206805783252231},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/EMA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-02-23","symbol":"EMA","fiscalQuarterEnding":"2025/12","expectedEps":0.43,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1771822800000,"reportTimeType":"pre","actualEps":0.4},{"date":"2026-01-30","symbol":"EMA","amount":0.7325,"announcedDate":"2026-01-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-01-30","defaultRemindTime":1769783400000,"name":"Emera Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-02-13","payableDate":"2026-01-30","currency":"CAD","dateTimestamp":1769749200000,"payDate":"2026-02-13"},{"market":"US","date":"2025-11-07","symbol":"EMA","fiscalQuarterEnding":"2025/09","expectedEps":0.61,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1762491600000,"reportTimeType":"pre","actualEps":0.64},{"date":"2025-10-31","symbol":"EMA","amount":0.7325,"announcedDate":"2025-10-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-10-31","defaultRemindTime":1761917400000,"name":"Emera Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-11-14","payableDate":"2025-10-31","currency":"CAD","dateTimestamp":1761883200000,"payDate":"2025-11-14"},{"market":"US","date":"2025-08-08","symbol":"EMA","fiscalQuarterEnding":"2025/06","expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1754625600000,"reportTimeType":"pre","actualEps":0.57}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"EMA\",market:\"US\",,,undefined,":[{"executeDate":"2016-04-28","recordDate":"2016-05-02","paymentDate":"2016-05-16","value":0.3682105,"currency":"USD"},{"executeDate":"2016-07-20","recordDate":"2016-07-22","paymentDate":"2016-08-15","value":0.4045038,"currency":"USD"},{"executeDate":"2016-10-28","recordDate":"2016-11-01","paymentDate":"2016-11-15","value":0.3880294,"currency":"USD"},{"executeDate":"2025-08-01","recordDate":"2025-08-01","paymentDate":"2025-08-15","value":0.725,"currency":"CAD"},{"executeDate":"2025-10-31","recordDate":"2025-10-31","paymentDate":"2025-11-14","value":0.7325,"currency":"CAD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"EMA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0.3333,"hold":0.6,"sell":0,"strongSell":0.0667,"meanLabel":"HOLD","meanPercent":0.6,"analysts":15,"updateTime":1769745600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/EMA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"EMA","date":"2026-03-27","current":20.842647,"percent":0.574879,"low":16.637027,"twenty":17.374599,"median":19.676248,"eighty":20.661152,"high":21.801642,"avg":19.284347,"sd":1.535952,"marketCap":15623406729.11},"quantilePoints":[{"date":"2025-05-30","current":19.76944,"twenty":19.76944,"median":19.76944,"eighty":19.76944,"marketCap":13505496352.43},{"date":"2025-06-06","current":19.324012,"twenty":19.535669,"median":19.692043,"eighty":19.76944,"marketCap":13350532994.37},{"date":"2025-06-13","current":19.308216,"twenty":19.137627,"median":19.324012,"eighty":19.722054,"marketCap":13371262392.6},{"date":"2025-06-20","current":19.245035,"twenty":19.160372,"median":19.387193,"eighty":19.674036,"marketCap":13211518175.96},{"date":"2025-06-27","current":19.308216,"twenty":19.224185,"median":19.382455,"eighty":19.560942,"marketCap":13348226238.04},{"date":"2025-07-03","current":19.469329,"twenty":19.242508,"median":19.399829,"eighty":19.679723,"marketCap":13533023992.92},{"date":"2025-07-11","current":19.753645,"twenty":19.282944,"median":19.43142,"eighty":19.706259,"marketCap":13611556279.78},{"date":"2025-07-18","current":19.592532,"twenty":19.308216,"median":19.502499,"eighty":19.712577,"marketCap":13439260670.95},{"date":"2025-07-25","current":20.116937,"twenty":19.317694,"median":19.614646,"eighty":19.767545,"marketCap":13920070443.21},{"date":"2025-08-01","current":20.552889,"twenty":19.356234,"median":19.663612,"eighty":19.931816,"marketCap":14004388886.88},{"date":"2025-08-08","current":20.884591,"twenty":19.383402,"median":19.706259,"eighty":20.124519,"marketCap":14315223696.17},{"date":"2025-08-15","current":20.686356,"twenty":19.389088,"median":19.714157,"eighty":20.375981,"marketCap":14241020029.57},{"date":"2025-08-22","current":21.111677,"twenty":19.401724,"median":19.753645,"eighty":20.511821,"marketCap":14434555399.62},{"date":"2025-08-29","current":20.468969,"twenty":19.420679,"median":19.785235,"eighty":20.581071,"marketCap":14130173597.74},{"date":"2025-09-05","current":20.484722,"twenty":19.429525,"median":19.883167,"eighty":20.585711,"marketCap":14060435241.25},{"date":"2025-09-12","current":20.283088,"twenty":19.441529,"median":20.015847,"eighty":20.549566,"marketCap":13928376571.28},{"date":"2025-09-19","current":19.923928,"twenty":19.461747,"median":20.073945,"eighty":20.542062,"marketCap":13714455884.59},{"date":"2025-09-26","current":20.585539,"twenty":19.495865,"median":20.087756,"eighty":20.542062,"marketCap":14040465233.16},{"date":"2025-10-03","current":21.108526,"twenty":19.558414,"median":20.183278,"eighty":20.617044,"marketCap":14341364686.36},{"date":"2025-10-10","current":21.127429,"twenty":19.601378,"median":20.281209,"eighty":20.758818,"marketCap":14318469638.17},{"date":"2025-10-17","current":21.666169,"twenty":19.623491,"median":20.300416,"eighty":20.797254,"marketCap":14653790731.95},{"date":"2025-10-24","current":21.757535,"twenty":19.646868,"median":20.374454,"eighty":20.916344,"marketCap":14770054950.94},{"date":"2025-10-31","current":21.360568,"twenty":19.663296,"median":20.386244,"eighty":21.06631,"marketCap":14513331426.12},{"date":"2025-11-07","current":21.272354,"twenty":19.674036,"median":20.41226,"eighty":21.097184,"marketCap":14296037747.86},{"date":"2025-11-14","current":17.374062,"twenty":19.601378,"median":20.386244,"eighty":21.06631,"marketCap":14568586353.81},{"date":"2025-11-21","current":17.212836,"twenty":19.441529,"median":20.374454,"eighty":21.041735,"marketCap":14368588864.66},{"date":"2025-11-28","current":17.407331,"twenty":19.394143,"median":20.301992,"eighty":21.030393,"marketCap":14577653448.13},{"date":"2025-12-05","current":16.921093,"twenty":19.311375,"median":20.282148,"eighty":21.003928,"marketCap":14257439118.84},{"date":"2025-12-12","current":16.693329,"twenty":19.18059,"median":20.230664,"eighty":20.983135,"marketCap":14234564864},{"date":"2025-12-19","current":17.167393,"twenty":17.900621,"median":20.102346,"eighty":20.957301,"marketCap":14657419004.37},{"date":"2025-12-26","current":17.216186,"twenty":17.458514,"median":20.073945,"eighty":20.944699,"marketCap":14789996894.17},{"date":"2026-01-02","current":17.370269,"twenty":17.373303,"median":20.0392,"eighty":20.932097,"marketCap":14871263471.89},{"date":"2026-01-09","current":17.43447,"twenty":17.368214,"median":19.923928,"eighty":20.903742,"marketCap":14773589152.84},{"date":"2026-01-16","current":17.439606,"twenty":17.353836,"median":19.83736,"eighty":20.887161,"marketCap":14748903694.51},{"date":"2026-01-23","current":17.57828,"twenty":17.358457,"median":19.76786,"eighty":20.862056,"marketCap":14967122519.73},{"date":"2026-01-30","current":17.452446,"twenty":17.36616,"median":19.731531,"eighty":20.822459,"marketCap":15149245081.41},{"date":"2026-02-06","current":17.639913,"twenty":17.358457,"median":19.706259,"eighty":20.792844,"marketCap":15150466223.22},{"date":"2026-02-13","current":17.632209,"twenty":17.329694,"median":19.687304,"eighty":20.780241,"marketCap":15197950382.19},{"date":"2026-02-20","current":18.01228,"twenty":17.336884,"median":19.662032,"eighty":20.776461,"marketCap":15461241242.05},{"date":"2026-02-27","current":19.370854,"twenty":17.349212,"median":19.603589,"eighty":20.77079,"marketCap":15419204876.87},{"date":"2026-03-06","current":19.860551,"twenty":17.357687,"median":19.614646,"eighty":20.758818,"marketCap":15772457447.89},{"date":"2026-03-13","current":20.172176,"twenty":17.364105,"median":19.663612,"eighty":20.731723,"marketCap":16126249798.12},{"date":"2026-03-20","current":19.982975,"twenty":17.371786,"median":19.706259,"eighty":20.697698,"marketCap":15868293252.05},{"date":"2026-03-27","current":19.866116,"twenty":17.374599,"median":19.676248,"eighty":20.661152,"marketCap":15623406729.11}],"updateTime":1774837253401},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"EMA\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2613786213","title":"Emera reports Q4 adjusted EPS 55c, consensus 42c","url":"https://stock-news.laohu8.com/highlight/detail?id=2613786213","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613786213?lang=en_us&edition=fundamental","pubTime":"2026-02-23 19:05","pubTimestamp":1771844757,"startTime":"0","endTime":"0","summary":"“Without question, 2025 was a strong year for Emera (EMA),” said Scott Balfour, CEO. “For the first time, we exceeded $1B in annual adjusted net in...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/emera-reports-q4-adjusted-eps-55c-consensus-42c-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/emera-reports-q4-adjusted-eps-55c-consensus-42c-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4081","EMA"],"gpt_icon":0},{"id":"2613378623","title":"Emera extends adjusted EPS growth target of 5%-7% through 2030","url":"https://stock-news.laohu8.com/highlight/detail?id=2613378623","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613378623?lang=en_us&edition=fundamental","pubTime":"2026-02-23 19:05","pubTimestamp":1771844727,"startTime":"0","endTime":"0","summary":"06:03 EST Emera (EMA) extends adjusted EPS growth target of 5%-7% through 2030 Published first on TheFly – the ultimate source for real-time, marke...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/emera-extends-adjusted-eps-growth-target-of-5-7-through-2030-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/emera-extends-adjusted-eps-growth-target-of-5-7-through-2030-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4081","EMA"],"gpt_icon":0},{"id":"2613863057","title":"Earnings Flash (EMA) Emera Posts Q4 Adjusted EPS CA$0.55, vs. FactSet Est of CA$0.57","url":"https://stock-news.laohu8.com/highlight/detail?id=2613863057","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613863057?lang=en_us&edition=fundamental","pubTime":"2026-02-23 19:02","pubTimestamp":1771844559,"startTime":"0","endTime":"0","summary":"Earnings Flash (EMA) Emera Posts Q4 Adjusted EPS CA$0.55, vs. FactSet Est of CA$0.57","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["EMA","CA","EMA.AU"],"gpt_icon":0},{"id":"2612406905","title":"AstraZeneca marketing authorization application for Enhertu validated by EMA","url":"https://stock-news.laohu8.com/highlight/detail?id=2612406905","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612406905?lang=en_us&edition=fundamental","pubTime":"2026-02-19 18:10","pubTimestamp":1771495835,"startTime":"0","endTime":"0","summary":"The European Medicines Agency has validated the Type II Variation marketing authorization application for Enhertu as a monotherapy for adult patien...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/astrazeneca-marketing-authorization-application-for-enhertu-validated-by-ema-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/astrazeneca-marketing-authorization-application-for-enhertu-validated-by-ema-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EMA","BK4081"],"gpt_icon":0},{"id":"2612446940","title":"NervGen Pharma to Participate at Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2612446940","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612446940?lang=en_us&edition=fundamental","pubTime":"2026-02-18 20:30","pubTimestamp":1771417800,"startTime":"0","endTime":"0","summary":"VANCOUVER, British Columbia, Feb.  18, 2026  (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company\") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing fi","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/18/3240099/0/en/NervGen-Pharma-to-Participate-at-Upcoming-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1291159041.SGD","BK4548","NGEN","EMA","LU0266013472.USD","BK4007","BK4192","LU1892829315.USD","LU1989771016.USD","BK4081","SCI","LU0077335932.USD"],"gpt_icon":0},{"id":"2612450057","title":"OS Therapies Discloses 2026 Timeline For Lead Drug Regulatory Filings","url":"https://stock-news.laohu8.com/highlight/detail?id=2612450057","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612450057?lang=en_us&edition=fundamental","pubTime":"2026-02-17 22:01","pubTimestamp":1771336860,"startTime":"0","endTime":"0","summary":"OS Therapies shares climb after new regulatory plans for OST-HER2 osteosarcoma treatment in the UK, EU, and U.S.","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/02/17/Various-Pharmaceuticals-Pills-Capsules-T.jpeg?optimize=medium&dpr=2&auto=webp&width=260","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/02/17/Various-Pharmaceuticals-Pills-Capsules-T.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/news/health-care/26/02/50649664/os-therapies-discloses-2026-timeline-for-lead-drug-regulatory-filings","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/26/02/50649664/os-therapies-discloses-2026-timeline-for-lead-drug-regulatory-filings","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["OSTX","BK4585","BK4217","BK4215","SMA","MAA","BK4588","BK4081","EMA","BK4139"],"gpt_icon":0},{"id":"2612845762","title":"Cellectar Biosciences Expands Global Intellectual Property Estate","url":"https://stock-news.laohu8.com/highlight/detail?id=2612845762","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612845762?lang=en_us&edition=fundamental","pubTime":"2026-02-17 21:05","pubTimestamp":1771333500,"startTime":"0","endTime":"0","summary":"Strengthens Protection Around Broad Portfolio of Cancer-Targeting Drug Conjugates and Enabling Technologies Provides Key Coverage Across Europe Ahead of Planned 3Q26 Filing for Conditional Marketing A","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/17/3239238/29076/en/Cellectar-Biosciences-Expands-Global-Intellectual-Property-Estate.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1481599808.USD","BK4585","IP","BK4123","LU1487256676.USD","LU1169590202.USD","LU2463526074.USD","BK4588","EMA","LU1481600234.SGD","CLRB","BK4139","CNS","LU1169589451.USD","IE00B3T34201.USD","BK4081","PDC","BK4135","BK4136"],"gpt_icon":0},{"id":"2612451744","title":"Shiba Inu (SHIB) Momentum Slows as Price Tests 200-EMA Resistance","url":"https://stock-news.laohu8.com/highlight/detail?id=2612451744","media":"utoday","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612451744?lang=en_us&edition=fundamental","pubTime":"2026-02-17 08:32","pubTimestamp":1771288320,"startTime":"0","endTime":"0","summary":"After weeks of declining pressure, Shiba Inu is attempting to stabilize, but there are always outside factors to consider. The 200-period EMA on the four-hour time frame is one of the chart's stronges","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"utodaynews_highlight","url":"https://u.today/shiba-inu-shib-momentum-slows-as-price-tests-200-ema-resistance","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://u.today/shiba-inu-shib-momentum-slows-as-price-tests-200-ema-resistance","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"utodaynews_highlight","symbols":["BK4081","EMA"],"gpt_icon":0},{"id":"1186620080","title":"Earning Preview: Emera Inc. Q4 revenue is expected to decrease by 52.39%, and institutional views are neutral-to-cautious","url":"https://stock-news.laohu8.com/highlight/detail?id=1186620080","media":"Earnings Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186620080?lang=en_us&edition=fundamental","pubTime":"2026-02-16 11:37","pubTimestamp":1771213032,"startTime":"0","endTime":"0","summary":"Abstract Emera Inc. will report its quarterly results on February 23, 2026 Pre-Market; this preview compiles the latest quarter’s performance, segment dynamics, and a consensus-aligned outlook for...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Earning Preview: Emera Inc. Q4 revenue is expected to decrease by 52.39%, and institutional views are neutral-to-cautious","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EMA"],"gpt_icon":0},{"id":"2611903908","title":"NervGen Pharma Announces Retirement of Chief Financial Officer, Bill Adams","url":"https://stock-news.laohu8.com/highlight/detail?id=2611903908","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611903908?lang=en_us&edition=fundamental","pubTime":"2026-02-13 05:15","pubTimestamp":1770930900,"startTime":"0","endTime":"0","summary":"VANCOUVER, British Columbia, Feb.  12, 2026  (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company\") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing fi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/12/3237692/0/en/NervGen-Pharma-Announces-Retirement-of-Chief-Financial-Officer-Bill-Adams.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","EMA","BK4081","LU1291159041.SGD","BK4548","NGEN","LU0266013472.USD","LU0077335932.USD","BK4192","SCI","LU1989771016.USD","LU1892829315.USD"],"gpt_icon":0},{"id":"2610929187","title":"Press Release: ORYZON Announces Appointment of Rolando Gutierrez-Esteinou, M.D., as Chief Medical Officer for CNS","url":"https://stock-news.laohu8.com/highlight/detail?id=2610929187","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610929187?lang=en_us&edition=fundamental","pubTime":"2026-02-12 21:00","pubTimestamp":1770901200,"startTime":"0","endTime":"0","summary":"-- Based in New Jersey , to lead ORYZON's CNS clinical development. MADRID and CAMBRIDGE, Mass., Feb. 12, 2026  -- Oryzon Genomics, S.A. , a clinical-stage biopharmaceutical company and global leader in epigenetics, today announced the appointment of Rolando Gutierrez-Esteinou, M.D., as Chief Medical Officer, CNS Programs. Dr. Gutierrez-Esteinou is a Harvard-trained psychiatrist and an accomplished global clinical development executive with more than 20 years of leadership experience advancing neuroscience and psychiatry-focused drug development programs. He brings deep expertise in late-stage clinical execution, regulatory strategy, and pathways to market approval.\"It is a privilege to join Oryzon as Chief Medical Officer and help advance vafidemstat, the onl","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4081","BK4022","EMA","BK4232","CNS","CMT","BK4156","ORR","BK4090","BK4135","USA","R"],"gpt_icon":0},{"id":"2610913763","title":"Press Release: Celyad Oncology Announces the Sale of C-CATHez (R) Catheter","url":"https://stock-news.laohu8.com/highlight/detail?id=2610913763","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610913763?lang=en_us&edition=fundamental","pubTime":"2026-02-12 14:00","pubTimestamp":1770876000,"startTime":"0","endTime":"0","summary":"Celyad Oncology  , today announced the acquisition by CellProthera of C-Cath  , the transendocardial catheter originally developed by Celyad Oncology. The acquisition is a decisive step for CellProthera as it prepares to enter Phase 3 clinical trial, with the transendocardial catheter as a cornerstone of its therapeutic approach, enabling targeted delivery of stem cells directly into damaged cardiac tissue. The transaction relates to all intellectual property rights and associated technical documentation.This release may contain forward-looking statements, including, without limitation, statements regarding beliefs about and expectations for the Company's updated strategic business model, including associated potential benefits, transactions and partnerships, statements regarding the potential value of the Company's IP, statements regarding the Company's financial statements and cash runway, statements regarding the Company's future fundraising plans, statements regarding the Company's","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["R","BK4022","EMA","BK4232","BK4081"],"gpt_icon":0},{"id":"2610137659","title":"Press Release: Ipsen delivers strong results in 2025, driven by solid execution across all therapeutic areas, and provides 2026 guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2610137659","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610137659?lang=en_us&edition=fundamental","pubTime":"2026-02-12 14:00","pubTimestamp":1770876000,"startTime":"0","endTime":"0","summary":"-- FY 2025 sales growth of 10.9% at CER1, or 8.1% as reported, driven by. growth of the three therapeutic areas of Oncology , Rare Disease.  and Neuroscience ; Somatuline sales growth of 4.3%1,with all other products, excluding Somatuline, achieving double-digit. -- FY 2025 core operating income of EUR1,294m, growing by 16.7% as reported,with a core operating margin of 35.2% of total sales, increasing by. -- 2025 continued pipeline expansion, driven by significant regulatory and. clinical milestones, integration of multiple preclinical assets with. global rights and innovative approaches, and a mid-stage candidate from. addition to the full data readout for IPN10200 in an aesthetics. PARIS, FRANCE, 12 February 2026 - Ipsen , a global specialty-care biopharmaceutical company, today presents its financial results for the full year  2025 and for the fourth quarter of 2025.\"In 2025, Ipsen delivered strong sales and profit growth,\" said David Loew, Chief Executive Officer, Ipsen. \"We contin","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4080","BK4231","BK4232","EMA","R","BK4022","BK4081","BOLD","ADC"],"gpt_icon":0},{"id":"2610962722","title":"Protalix Highlights Positive EMA Opinion on Elfabrio Dosing","url":"https://stock-news.laohu8.com/highlight/detail?id=2610962722","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610962722?lang=en_us&edition=fundamental","pubTime":"2026-02-12 06:28","pubTimestamp":1770848911,"startTime":"0","endTime":"0","summary":"Protalix ( ($PLX) ) just unveiled an announcement. On February 11, 2026, Protalix BioTherapeutics posted an updated corporate presentation outlinin...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/protalix-highlights-positive-ema-opinion-on-elfabrio-dosing?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/protalix-highlights-positive-ema-opinion-on-elfabrio-dosing?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EMA","BK4081"],"gpt_icon":0},{"id":"2610295288","title":"Desjardins Sticks to Their Hold Rating for Emera (EMA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2610295288","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610295288?lang=en_us&edition=fundamental","pubTime":"2026-02-12 00:35","pubTimestamp":1770827716,"startTime":"0","endTime":"0","summary":"In a report released today, Brent Stadler from Desjardins maintained a Hold rating on Emera, with a price target of C$68.00. According to TipRanks,...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/desjardins-sticks-to-their-hold-rating-for-emera-ema-blurbs-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/desjardins-sticks-to-their-hold-rating-for-emera-ema-blurbs-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EMA"],"gpt_icon":0},{"id":"2610932627","title":"NervGen Pharma to Present at Unite2Fight Paralysis’ 20th Annual Science and Advocacy Symposium","url":"https://stock-news.laohu8.com/highlight/detail?id=2610932627","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610932627?lang=en_us&edition=fundamental","pubTime":"2026-02-11 20:00","pubTimestamp":1770811200,"startTime":"0","endTime":"0","summary":"Adam Rogers, MD, President and Chief Executive Officer of NervGen to present and discuss clinical data from the Phase 1b/2a CONNECT SCI Study demonstrating durable improvement in function, independenc","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/11/3236120/0/en/NervGen-Pharma-to-Present-at-Unite2Fight-Paralysis-20th-Annual-Science-and-Advocacy-Symposium.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","LU1291159041.SGD","LU1892829315.USD","LU1989771016.USD","LU0077335932.USD","NGEN","LU0266013472.USD","BK4081","EMA","BK4007","BK4192","SCI"],"gpt_icon":0},{"id":"2610623581","title":"Enlivex Treasury Portfolio Update: New Listing of the RAIN Token on Kraken, the Second-Largest U.S. Cryptocurrency Exchange","url":"https://stock-news.laohu8.com/highlight/detail?id=2610623581","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610623581?lang=en_us&edition=fundamental","pubTime":"2026-02-10 21:00","pubTimestamp":1770728400,"startTime":"0","endTime":"0","summary":"Additional exchange listing expected to increase token access and contribute to expanded secondary market liquidity for RAIN Nes-Ziona, Israel, Feb.  10, 2026  (GLOBE NEWSWIRE) --  Enlivex Therapeutic","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/10/3235274/0/en/Enlivex-Treasury-Portfolio-Update-New-Listing-of-the-RAIN-Token-on-Kraken-the-Second-Largest-U-S-Cryptocurrency-Exchange.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAIN","BK4161","BK4007","BK4539","BK4081","EMA"],"gpt_icon":0},{"id":"2610377526","title":"NervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company’s Growth and Execution of Its Mission in Spinal Cord Injury","url":"https://stock-news.laohu8.com/highlight/detail?id=2610377526","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610377526?lang=en_us&edition=fundamental","pubTime":"2026-02-09 20:00","pubTimestamp":1770638400,"startTime":"0","endTime":"0","summary":"VANCOUVER, British Columbia, Feb.  09, 2026  (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company\") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing fi","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/09/3234390/0/en/NervGen-Pharma-Appoints-Adam-Rogers-as-Chief-Executive-Officer-to-Continue-Leading-the-Company-s-Growth-and-Execution-of-Its-Mission-in-Spinal-Cord-Injury.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SCI","NGEN","LU0266013472.USD","CEO","BK4192","BK4081","EMA","BK4548","LU1892829315.USD","LU1291159041.SGD","LU0077335932.USD","LU1989771016.USD","BK4007"],"gpt_icon":0},{"id":"2609384536","title":"Neuren's Regulatory Hurdles for Trofinetide May Push Back EU Royalties, Says Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2609384536","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609384536?lang=en_us&edition=fundamental","pubTime":"2026-02-06 08:13","pubTimestamp":1770336816,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals  facing regulatory uncertainty in the European Union  for its investigational drug trofinetide to treat Rett syndrome may delay royalties from sales in the region, Jefferies said in a note on Thursday.The European Medicines Agency  Committee for Medicinal Products for Human Use  gave a negative trend vote this week on the drug candidate's market authorization application, possibly due to concerns about the effect size in the confirmatory trial.Jefferies said the negative trend vote is an early indication that the regulatory authority might issue a negative opinion on the application at the final vote.The investment firm now expects royalties from EU sales of trofinetide to kick in the fourth quarter of fiscal 2026, and not second quarter.Meanwhile, it projects Neuren's experimental drug NNZ-2591 for treating Pitt-Hopkins Syndrome, a rare neurodevelopmental disorder, will receive reimbursement approval in the US in fiscal 2029.Jefferies lowered the company's fisca","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4087","BK4081","BK7508","EMA.AU","BK7096","BK7129","CHMP","EMA","NEU.AU","BK4156"],"gpt_icon":0},{"id":"2608549573","title":"Neuren Pharmaceuticals (ASX:NEU) Is Down 16.1% After EMA Setback on Trofinetide Approval Prospects","url":"https://stock-news.laohu8.com/highlight/detail?id=2608549573","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608549573?lang=en_us&edition=fundamental","pubTime":"2026-02-04 14:24","pubTimestamp":1770186248,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals’ partner Acadia Pharmaceuticals recently received a negative trend vote from the European Medicines Agency’s Committee for Medicinal Products for Human Use on trofinetide’s marketing authorisation application for Rett syndrome in Europe, and Acadia plans to request a re-examination of the decision.\nThis setback highlights how regulatory assessments can differ across regions even for a rare-disease therapy already approved in the US, Canada and Israel, adding...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-neu/neuren-pharmaceuticals-shares/news/neuren-pharmaceuticals-asxneu-is-down-161-after-ema-setback","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-neu/neuren-pharmaceuticals-shares/news/neuren-pharmaceuticals-asxneu-is-down-161-after-ema-setback","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["EMA","BK7508","BK7096","BK4109","BK4081","NEU.AU","NEU"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":4,"totalSize":200,"code":"91000000","status":"200"}]}}